StemRIM Inc.
4599 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 茨木市彩都あさぎ７丁目７番１５号
- Website:
- https://stemrim.com/english/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
StemRIM Inc. is a pioneering biotechnology company dedicated to revolutionizing regenerative medicine with its proprietary approach known as “Regeneration-Inducing Medicine™.” Focused on providing hope for patients suffering from intractable diseases, StemRIM harnesses the human body's innate healing capabilities to promote the functional regeneration of tissues and organs. By developing innovative therapies that recruit the patient's own in-vivo stem cells to damaged areas, the company aims to restore health without relying on traditional cell-therapy methods. Through cutting-edge research and a commitment to advancing medical science, StemRIM is poised to create a brighter future for patients in need of effective, regenerative solutions.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-03-13 04:31 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB | |
| 2025-03-13 04:30 |
Interim Report
半期報告書－第20期(2024/08/01－2025/07/31)
|
Japanese | 228.6 KB | |
| 2024-11-25 08:13 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 49.5 KB | |
| 2024-11-18 01:31 |
Regulatory News Service
訂正臨時報告書
|
Japanese | 32.6 KB | |
| 2024-11-13 08:10 |
Inside Information Statement
臨時報告書
|
Japanese | 36.2 KB | |
| 2024-10-31 05:28 |
Inside Information Statement
臨時報告書
|
Japanese | 22.4 KB | |
| 2024-10-31 03:35 |
Internal Control over Financial Reporting
内部統制報告書－第19期(2023/08/01－2024/07/31)
|
Japanese | 21.0 KB | |
| 2024-10-31 03:35 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-10-31 03:32 |
Annual Report
有価証券報告書－第19期(2023/08/01－2024/07/31)
|
Japanese | 2.7 MB | |
| 2024-07-26 08:53 |
Inside Information Statement
臨時報告書
|
Japanese | 35.7 KB | |
| 2024-07-26 08:53 |
Inside Information Statement
臨時報告書
|
Japanese | 35.8 KB | |
| 2024-07-25 02:46 |
Inside Information Statement
臨時報告書
|
Japanese | 21.7 KB | |
| 2024-06-13 02:57 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB | |
| 2024-06-13 02:56 |
Quarterly Report
四半期報告書－第19期第3四半期(2024/02/01－2024/04/30)
|
Japanese | 166.9 KB | |
| 2024-03-14 03:47 |
Quarterly Report
四半期報告書－第19期第2四半期(2023/11/01－2024/01/31)
|
Japanese | 236.2 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP | |
| ASKA Pharmaceutical Holdings CO., Ltd. | Japan | 4886 | ||
|
Astellas Pharma Inc. | Japan | 4503 | |
|
AstraZeneca PLC | United Kingdom | AZN | |
|
Basilea Pharmaceutica AG | Switzerland | BSLN | |
|
Bayer AG | Germany | BAY | |
|
Biofarm S.A. | Romania | BIO | |
|
Biogened Spolka Akcyjna | Poland | BGD |